Return to content in this issue

 

Safe administration of SARS-CoV-2 vaccine after desensitization to a biologic containing polysorbate 80 in a patient with polyethylene glycol-induced severe anaphylaxis and sensitization to polysorbate 80

Nin-Valencia A1, Fiandor A1,2,3, Lluch M1,2,3, Quirce S1,2,4, Caballero T1,2,5, Heredia Revuelto R1, González-Muñoz M2,6, Caballero ML1,2, Cabañas R1,2,3,5

1Department of Allergy, Hospital Universitario La Paz, Madrid, Spain.
2Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
3PIELenRed Consortium.
4Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES)
5Centro de Investigación en Red de Enfermedades Raras (CIBERER, U754).
6Department of Immunology, Hospital Universitario La Paz, Madrid, Spain.

J Investig Allergol Clin Immunol 2023; Vol. 33(2)
doi: 10.18176/jiaci.0830

Key words: Polyethylene glycol, Polysorbates, Allergy, Desensitization, Infliximab, SARS-CoV-2 vaccine